| Document |
Document Title |
|
WO/2018/202689A1 |
The present invention relates to a process for the preparation of particular 2-(2H-[1,2,3]triazol-2-yl)-benzoic acid derivatives of formula (I), to certain crystalline forms of potassium salts of said 2-(2H-[1,2,3]triazol-2-yl)-benzoic a...
|
|
WO/2018/199562A1 |
The present invention relates to a 2-amino-2-(1-(2-(2-hydroxyethoxy)ethyl)-1H-1,2,3-triazole-4-
yl)propane-1,3-diol derivative which is a novel compound represented by chemical formula 1, and a use thereof. The novel compound of chemical...
|
|
WO/2018/193385A1 |
The present invention relates to 4-substituted phenylamidine derivatives of the general formula (I), wherein R5-R6, ArA4, D, G, B, Q and an integer m have the meanings as defined in the description. The invention further relates to metho...
|
|
WO/2018/190281A1 |
Provided are benzotriazole derivative compounds of the general formula that are novel compounds capable of strongly absorbing light in the ultraviolet range, particularly 300-330 nm, while strongly absorbing light in the visible light sh...
|
|
WO/2018/189340A1 |
The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (...
|
|
WO/2018/187480A1 |
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, ab...
|
|
WO/2018/184579A1 |
The present invention provides a triazole compound and use thereof in agriculture. In particularly, the present invention provides a triazole compound having Formula (A) and a preparation method thereof, a composition and formulation con...
|
|
WO/2018/186365A1 |
The present invention relates to a novel read-through inducing agent, and also relates to a compound represented by general formula (I) (symbols in the formula are as described in the specification) or a pharmaceutically accepted salt th...
|
|
WO/2018/178384A1 |
The invention relates to a compound of formula (I): A-B-D-E (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein: A is selected from monocyclic and bicyclic h...
|
|
WO/2018/176202A1 |
The invention provides a method for preparing an additive represented by formula (I) used in polymers. The method includes the following steps: (a) adding phosphorus tribromide to a compound of formula (II) in the presence of a solvent c...
|
|
WO/2018/180632A1 |
The present invention provides a benzotriazole derivative compound represented by a general formula (wherein R3 represents an alkyl group, and R4 represents an acryloyloxyalkyl group or a methacryloyloxyalkyl group), as a novel compound ...
|
|
WO/2018/170306A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2018/162806A1 |
The present invention relates to a compound of formula (I): (I) as defined in the description. The present invention also relates to a method for extracting biological membrane-associated membrane proteins, comprising a step of bringing ...
|
|
WO/2018/159835A1 |
The present invention provides a strigolactone receptor inhibitor for plants, which contains, as effective component, at least one triazole urea compound represented by formula (I); an agricultural composition; a method for using this ag...
|
|
WO/2018/151678A1 |
The present invention relates to heterocyclic compounds having the general Formula (I) wherein W1, W2, W3, W4, W7, W8, R1, R2, R3, R4, X2, X3, X4, Z1, Z2, Z3, Q, n and m are as defined herein, or a pharmaceutically acceptable salt thereo...
|
|
WO/2018/150335A1 |
The present invention relates to novel co-crystals of lesinurad with nicotinamide, urea, and caffeine; methods for their preparation, pharmaceutical compositions and method of use thereof.
|
|
WO/2018/129552A1 |
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-sta...
|
|
WO/2018/122325A1 |
The present invention pertains to a system of collaborative modifiers that are assembled into a multi molecule complex in vivo within a cell using bioorthogonal chemical reactions. The system of the invention is composed of multiple bind...
|
|
WO/2018/124172A1 |
A method is provided by which an alcohol compound having a satisfactory purity is obtained from an ester compound in a simple manner. A high-purity alcohol compound can be obtained by: passing a solution which contains both an ester comp...
|
|
WO/2018/121560A1 |
The present invention relates to a urea compound and a preparation method and an application thereof. The structure of the present compound is represented by formula (I), the definition of each variable in the formula being as described ...
|
|
WO/2018/117063A1 |
[Problem] To provide a medicine, in particular, a medicine that is useful for treating agitation. [Solution] The present inventors conducted intensive studies to provide a therapeutic agent for agitation. As a result, they found that 4-{...
|
|
WO/2018/116107A1 |
Provided are IDO inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases ...
|
|
WO/2018/118736A1 |
The present invention is directed to 6,5-fused heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described he...
|
|
WO/2018/109649A1 |
The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and...
|
|
WO/2018/108695A1 |
The present invention relates to phenyltriazolinones of formula (I) (I), or their agriculturally acceptable salts or derivatives,wherein the variables are defined according to the description, processes and intermediates for preparing th...
|
|
WO/2018/106646A1 |
The invention relates to triazole compounds of formula (I') or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: wherein A is selected from the group consisting of (i), (ii), (iii), (iv), (v), and...
|
|
WO/2018/103757A1 |
Provided is a CCR2/CCR5 receptor antagonist and the use thereof in the preparation of a drug for treating diseases associated with the CCR2/CCR5. In particular, disclosed are a compound represented by formula (I) and a pharmaceutically a...
|
|
WO/2010/056999A9 |
The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives substantially enriched in an enantiomer of formula (I): wherein R3, R4, R5, R6, R7, R13a, R13b, R14a, R14b, P, Q, V, W, X, Y, Z and a are as defined in the...
|
|
WO/2018/099416A1 |
Provided in the present invention are an azo-compound, a polymer and a preparation method and a use. The structural formula of the azo-compound is shown in formula (I), wherein R1、R2、R3 and m have meanings as described in the descrip...
|
|
WO/2018/098207A1 |
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
|
|
WO/2018/093579A1 |
Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions...
|
|
WO/2018/089402A1 |
There are described RORγ Gamma modulators of the formula (I), (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutic...
|
|
WO/2018/087019A1 |
The invention relates to a method for producing amide bonds, particularly peptide bonds, with the aid of new amide coupling reagents containing an anion of formula (I); the invention also relates to these new reagents and to the producti...
|
|
WO/2018/085932A1 |
The present invention provides novel crystalline forms of Lesinurad, pharmaceutical compositions comprising these crystalline forms, and their use in the treatment of hyperuricemia associated with gout. Specific crystalline forms provide...
|
|
WO/2018/077923A1 |
The present invention provides triazolone compounds compounds of general formula (I) : in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds,...
|
|
WO/2018/081425A1 |
Described herein are compounds having a hydrogen-bonding group and optionally a functional group for binding (e.g., covalently binding) the compound to another compound (e.g., hyaluronic acid and/or gelatin). A compound of the present in...
|
|
WO/2018/067764A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such molecules and intermediates used in such processes, compositions containi...
|
|
WO/2018/065341A1 |
Disclosed is a method for preparing an ultraviolet radiation absorbing polymer composition comprising the polymer compound of formula in an esterification / transesterification which method comprises the steps of reacting a polyglycerol ...
|
|
WO/2018/067615A1 |
The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are i...
|
|
WO/2018/062978A1 |
The present invention relates to a novel heteroaryl compound, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof, and an antiviral composition comprising the same as an active ingredient. The novel compounds repr...
|
|
WO/2018/060704A1 |
Compounds of Formula (I), which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) are provided. Methods and uses of these compounds for the treatment or prevention of disorders requiring a reduct...
|
|
WO/2018/060070A1 |
The present invention relates to novel triazole derivatives, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmf...
|
|
WO/2018/053587A1 |
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.
|
|
WO/2018/051252A2 |
An object of the present invention is to provide an amide compound or a salt thereof that controls a mite. The present invention provides an amide compound represented by Formula (1) : or a salt thereof, wherein R1 represents C1-6 alkyl ...
|
|
WO/2018/051278A2 |
The present invention relates to a compound of formula (I) based on enamine derivatives and used as organic hole conductors or hole transporting material in an optoelectronic or photoelectrochemical device. The present invention relates ...
|
|
WO/2018/045182A1 |
The present disclosure provides compounds that may be useful for inhibiting Wnt pathway comprising compounds of the formula: (Ia) or (Ib) wherein the variables are as defined herein. In some aspects, the compounds may be used to inhibit ...
|
|
WO/2018/042342A1 |
The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, G, L, R1, Rx, Ry, X1, X2, X3, X4, n, p, q and t are as defined herein, which are active as modulators of retino...
|
|
WO/2018/035291A1 |
The present invention relates to 1,2,4-triazolidine-3-thione compounds, compositions, and methods for the treatment or prevention of bacterial infections (for example, bacterial infections due to Acinetobacter).
|
|
WO/2018/029150A1 |
The invention relates to compounds acting as agonists of G-protein coupled receptor 120 (GPR120) and/or 40 (GPR40), and having formula (I). Said compounds are useful in the treatment of diseases or disorders modulated by GPR120 and/or GP...
|
|
WO/2018/024188A1 |
Provided are a polycyclic compound and a manufacturing method, pharmaceutical composition, and application thereof. The structure of the polycyclic compound and an isomer, prodrug, solvate, hydrate, stable isotopic derivative, or pharmac...
|
